



# Com|PI|i|t DX Liquid

## SAMPLE INFORMATION

|                      |        |                           |                    |
|----------------------|--------|---------------------------|--------------------|
| <b>Name</b>          | -      | <b>Date Sp. Extracted</b> | -                  |
| <b>ID/Medical ID</b> | -      | <b>Req. Physician</b>     | -                  |
| <b>Date of Birth</b> | -      | <b>Report No</b>          | 26xxxxxxGR         |
| <b>Material #1</b>   | PLASMA | <b>Date Received</b>      | -                  |
| <b>Material #2</b>   | -      | <b>Date of Report</b>     | -                  |
| <b>Sample #1 ID</b>  | -      | <b>Tumor type</b>         | CHOLANGIOCARCINOMA |

**Com.PL.i.t. Dx Liquid Biopsy (14 genes, 7 fusions) | Comprehensive Panel for Individualized Treatment**

## 1. Clinically Significant Biomarkers\*

| Biomarker                               | Result                        | Therapies with strong clinical significance    |                                             | Therapies with potential significance          | Therapies with potential resistance |
|-----------------------------------------|-------------------------------|------------------------------------------------|---------------------------------------------|------------------------------------------------|-------------------------------------|
|                                         |                               | Approved/ Standard of care therapies (Level A) | Therapies in well powered studies (Level B) | Off label/ Investigational therapies (Level C) |                                     |
| <b>KRAS</b>                             | Exon 3<br>p.Q61H<br>VAF: 0.6% | -                                              | -                                           | Avutometinib+Defactinib                        | -                                   |
| <b>Microsatellite Instability (MSI)</b> | Stable (MSS)                  | -                                              | -                                           | -                                              | -                                   |

\*Note: Variants' Level of Evidence (LoE) (e.g. A, B, C etc) are based on the Joint consensus recommendation of AMP, ACMG, ASCO and CAP for reporting genetic variants in cancer. For a detailed description of the recommendation please refer to Fig. 1



# Com|PI|i|t DX Liquid

| Name | - | Report No | 26xxxxxxGR |
|------|---|-----------|------------|
|------|---|-----------|------------|

1. [Clinically Significant Biomarkers](#)
2. [Methodology](#)
3. [Quality Control Results](#)
4. [Important biomarkers findings](#)
5. [Immune Checkpoint inhibitors biomarkers](#)
6. [Interpretations for targeted therapies](#)
7. [Clinical Trials to consider](#)
8. [Appendix](#)
9. [Biomarker findings across all Levels of evidence \(A-D\)](#)
10. [References](#)



# Com|Pl|i|t DX Liquid

Name - Report No 26xxxxxxGR

## 2. Methodology

### NGS analysis

ctDNA analysis was performed using plasma-extracted cfDNA. The MagMAX Cell-Free DNA Isolation Kit (ThermoFischer Scientific) was used for cfDNA. A capture based targeted next generation sequencing (NGS) analysis was performed, using the Oncology 188-Gene Variant Assay (GenePlus) which is a qualitative test which enables the simultaneous detection of single nucleotide variants (SNVs), insertions and deletions (Indels), fusions and copy number variations (CNVs) as well as microsatellite instability (MSI) in a single workflow.

Sequencing was carried out on the DNBSEQ-T7 NGS platform (MGI). The analysis of 14 genes includes the entire exon regions and CNVs of 5 genes, partial exon regions of 9 genes and introns/promoters/fusion breakpoint regions of 7 genes. The test also reports on Microsatellite Instability (MSI) status.

Sequencing data are analyzed through bioinformatics pipeline for variant calling and interpretation using the Gene+Box data analysis and management system. Alteration- and tumor type-specific therapeutic implications are classified using the OncoKB™ Levels of Evidence system, which assigns clinical actionability to individual mutational events. For additional details about the OncoKB™ curation process, please refer to the version-controlled OncoKB™ Curation Standard Operating Procedure.

### Genes Analyzed

| 14 Gene Alterations |         |        |        |       |       |      |     |     |       |
|---------------------|---------|--------|--------|-------|-------|------|-----|-----|-------|
| BRAF*               | CDKN2A* | CTNNB1 | ERBB2* | IDH1  | IDH2  | KRAS | MET | NF1 | PTEN* |
| TERT                | TSC1    | TSC2   | TP53*  |       |       |      |     |     |       |
| 7 Fusion Genes      |         |        |        |       |       |      |     |     |       |
| FGFR1               | FGFR2   | FGFR3  | NTRK1  | NTRK2 | NTRK3 | RET  |     |     |       |
| MSI                 |         |        |        |       |       |      |     |     |       |

\*CNV (amplification/deletion) analysis is included for these genes

**Sensitivity:** Positive reference standards are tested with the assay, all corresponding mutation sites can be accurately detected, and the positive percent agreement (PPA) for all variants (SNVs, Indels, fusions and CNVs) assessed was 95%.

**Specificity:** Negative reference standards are tested with the assay, and the negative percent agreement (NPA) of SNVs, Indels, fusions and CNVs was 99%.

**Limit of Detection (LoD):** The limit of detection (LoD) of this assay is listed in the table below. The LoD is based on as low as 30ng cfDNA input for library preparation.



# Com|Pl|i|t DX Liquid

|             |   |                  |            |
|-------------|---|------------------|------------|
| <b>Name</b> | - | <b>Report No</b> | 26xxxxxxGR |
|-------------|---|------------------|------------|

The performance characteristics of the assay are summarized in the following table:

| Variant Type                       | Limit of Detection |
|------------------------------------|--------------------|
| Single nucleotide variations (SNV) | VAF $\geq$ 0.2%    |
| Insertions/deletions (Indel)       | VAF $\geq$ 0.2%    |
| Fusion (or rearrangement)          | VAF $\geq$ 0.5%    |
| Copy number (CNV)                  | $\geq$ 2.4 copies  |

## Disclaimer

1. This test is mainly used to assist clinical decision-making, and the result does not represent clinical decision.
2. The test should be interpreted by combining the actual patient context. The medication information provided only on the basis of genetic test results, and the actual medication should follow the physician's instructions.
3. The clinical trials only present partial relevant clinical recruitment trials. For more comprehensive and updated information, please refer to the website: <https://clinicaltrials.gov/>.
4. As evidence on variants and drugs evolves, previous classifications may later be modified. The interpretation of a variant is based on current available evidence.
5. Sequence variants were reported using Human Genome Variation Society (HGVS) nomenclature. Classification and interpretation of variants follow guidelines of American College of Medical Genetics and Genomics (ACMG), Association of Molecular Pathology (AMP), American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP).
6. Database and references used: Reference genome (GRCh37), annotation using A Locus Reference Genomic (LRG), database referencing 1000G (phaseIII-ucsc), EXAC (0.3.1), dbSNP (147), PolyPhen2/SIFT (ensdb v73), PhyloP (2013-12-06), Clinvar (2018-8) and Cosmic(V80).

## Limitations

1. The test is limited to test genomic variations on DNA level and does not involve RNA level or protein level.
2. Limited cell free tumor DNA (ctDNA) amount could result in false negative results.
3. Scientific data show that not all patients carry genomic variations that are associated with targeted drug, therefore not all subjects can be matched with targeted therapies or clear resistance mechanism.
4. Genetic variation beyond the detection range of this test or some non-gene mutation related factors such as drug interactions may affect the clinical effects of drugs.
5. Every molecular test has an internal 0.5-1% chance of failure. This is due to rare molecular events and factors related to the preparation and analysis of the samples.
6. Improper sample collection, transportation and storage may lead to compromised or invalid results.



52, Spaton Ave., 15344, Gerakas, Greece, G.E.MI. nr: 0007856001000 | [info@genekor.com](mailto:info@genekor.com), [www.genekor.com](http://www.genekor.com) | Tel. (+30) 210 6032138 Fax. (+30) 210 6032148  
A company certified with ISO 9001:2015 (Cert. No 041150049) and ISO/IEC 27001:2022 (Cert. No 048190009)

**George Nasioulas, PhD Molecular Biologist, Scientific Director, Medical ID:26025301255**

Document Code: Δ21\_CCA\_Liquid



# Com|PI|i|t DX Liquid

Name - Report No 26xxxxxxGR

### 3. Quality Control Results

| Quality Control Index           |                                                    | Result       | Criterion |
|---------------------------------|----------------------------------------------------|--------------|-----------|
| Sequencing Quality Assessment   | Average effective sequencing depth <sup>1</sup>    | <b>12653</b> | ≥10000    |
|                                 | Fraction of target covered with ≥500x <sup>2</sup> | 100%         | ≥90%      |
|                                 | Fraction of base quality ≥Q30 <sup>3</sup>         | 99%          | ≥80%      |
| Overall Assessment <sup>4</sup> |                                                    | PASS         |           |

**Note:**

1. Average effective sequencing depth: Average sequencing depth on target without duplicated reads.
2. Fraction of target covered with ≥ 500x: The proportion of bases that sequencing depth reach or above 500x on target, this index reflecting the coverage uniformity of sequencing.
3. Fraction of base quality ≥ Q30: The proportion of base quality in sequencing data that reach or above Q30, that is the probability of base recognition accuracy rate exceeds 99.9%.
4. Overall Assessment: The quality control overall assessment results are divided into two levels: "PASS" and "RISK". When the overall quality assessment result is "RISK", 94-96% of coverage was achieved in the genes analysed, hence there is a small range where clinical actionable variations could be undetected.



# Com|PI|i+t DX Liquid

Name - Report No 26xxxxxxGR

## 4. Important biomarkers findings

| Gene                       | Finding (VAF) | Gene                           | Finding (VAF) |
|----------------------------|---------------|--------------------------------|---------------|
| <i>BRAF_V600E</i>          | Not Detected  | <i>NTRK1/2/3</i> rearrangement | Not Detected  |
| <i>ERBB2</i> amplification | Not Detected  | <i>MSI</i> status              | <b>MSS</b>    |
| <i>FGFR2</i> rearrangement | Not Detected  | <i>RET</i> rearrangement       | Not Detected  |
| <i>IDH1</i> mutation       | Not Detected  |                                |               |

## 5. Immune Checkpoint inhibitors biomarkers

| Biomarker/Variant                              | Result       | Clinical Interpretation |
|------------------------------------------------|--------------|-------------------------|
| <b>Treatment effect - positive correlation</b> |              |                         |
| <i>MSI</i> status                              | MSS          | -                       |
| <i>TP53</i> mutation                           | Not Detected | -                       |
| <b>Treatment effect - negative correlation</b> |              |                         |
| <i>ALK</i> rearrangement                       | Not Detected | -                       |
| <i>PTEN</i> inactivating mutation              | Not Detected | -                       |

Com|PI|i+t DX Liquid

Name-

Report No26xxxxxxGR

6. Interpretations for targeted therapies

Genetic Variation:KRAS: c.183A>C (p.Q61H)

VAF\*: 0.6%

OncoKB

Treatment Information

Avutometinib is an inhibitor of Ras-Raf-MEK-ERK signaling being developed as a potential treatment for cancer. Defactinib is a small-molecule, oral focal adhesion kinase (FAK) inhibitor. It works by blocking FAK, a tyrosine kinase involved in cell adhesion and signaling pathways, including RAS/MEK/ERK and PI3K/Akt. Defactinib has been studied in various clinical trials for its potential anti-tumor and anti-angiogenic activities. In 2025 FDA approved defactinib in combination with avutometinib for the treatment of adult patients with recurrent low-grade serous ovarian cancer. A phase I clinical trial of RMC-6236 in patients with advanced refractory solid cancers harboring specific KRAS mutations is ongoing (NCT05379985). Setidegrasib, formerly known as ASP3082, is a first-in-class KRAS G12D-targeted protein degrader. Unlike traditional inhibitors that block protein activity, setidegrasib tags the mutant KRAS G12D protein for destruction, effectively removing the oncogenic driver from cancer cells and showing promise in treating pancreatic and non-small cell lung cancers. Daraxonrasib is an investigational drug for cancers with RAS mutations, including Cholangiocarcinoma with KRAS G12 mutations, and it is not yet FDA-approved. In early trials, it showed a 38% overall response rate in patients with RAS-mutant NSCLC, with a median response duration of 15.1 months. It is being investigated in Phase 3 trials against docetaxel for patients with previously treated, RAS-mutant NSCLC. There are promising clinical data in patients with non-small cell lung cancer with a KRAS G12 mutation treated with the pan-RAS targeted inhibitor daraxonrasib. To date, most efforts to treat cancers with RAS mutations (with the exception of G12C), have focused on targeting downstream effectors of mutant RAS, such as RAF, MEK, or PI3K, each of which is druggable. MEK inhibitors have been the most widely investigated, typically as a combination therapy, despite the presence of multiple inhibitors that are being explored to target different KRAS-activated pathways (PMID: 33402199). The most common MEK inhibitors used in clinical practice are cobimetinib, binimetinib and trametinib. Cobimetinib is a kinase inhibitor, approved by the FDA, for use in combination with vemurafenib for the treatment of advanced melanoma with a BRAF V600E or V600K mutation (IMspire150, NCT02908672). An initial phase Ib study (NCT01988896) was conducted to investigate the safety and efficacy of cobimetinib plus atezolizumab for patients with solid tumors, 28 NSCLC patients included. Atezolizumab plus cobimetinib had manageable safety and clinical activity irrespective of KRAS/BRAF status (PMID: 30918950). Binimetinib is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor, which is approved by the FDA in combination with encorafenib for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations (COLUMBUS; NCT01909453). The MEK inhibitor binimetinib has been examined in a number of clinical trials for patients with KRAS-mutated lung cancer, including studies looking at the agent in combination with chemotherapy (NCT02185690 PMID: 34052705 NCT02964689-completed/results non posted) and with palbociclib (NCT03170206-ongoing). Trametinib is a kinase inhibitor, approved by the FDA, for the treatment of melanoma, non-small cell lung cancer, thyroid cancer, and solid tumors with BRAF V600 mutations (METRIC study). The efficacy of MEK inhibitor trametinib, alone or in combination with docetaxel, has been evaluated in KRAS-mutant NSCLC. Trametinib plus docetaxel had encouraging results. Trametinib is being examined with the PD-1 inhibitor pembrolizumab in the phase Ib/II IM-BATTLE-2 trial (NCT03225664).

Gene information

KRAS is a member of the RAS family of small GTPases, which catalyze the hydrolysis of GTP to GDP. Under physiologic conditions, these RAS proteins cycle between an active (GTP-bound) and an inactive (GDP-bound) state, to activate the MAPK and PI3K



52, Spaton Ave., 15344, Gerakas, Greece, G.E.MI. nr: 0007856001000 | info@genekor.com, www.genekor.com | Tel. (+30) 210 6032138 Fax. (+30) 210 6032148  
A company certified with ISO 9001:2015 (Cert. No 041150049) and ISO/IEC 27001:2022(Cert. No 048190009)

George Nasioulas, PhD Molecular Biologist, Scientific Director, Medical ID:26025301255

Document Code: Δ21\_CCA\_Liquid



# Com|PI|i|t DX Liquid

Name

-

Report No

26xxxxxxGR

oncogenic pathway signaling downstream of Receptor Tyrosine Kinases (RTKs) (PMID: [22189424](#)). The function of RAS enzymes is regulated by guanine nucleotide exchange factors (GEFs), such as SOS, which enable the exchange of GDP to GTP, as well as by GTPase activating proteins, such as NF1, which increase the ability of RAS to hydrolyze GTP. Once activated, RAS mediates the regulation of cellular proliferation and other cellular functions through the activation of distinct intracellular signaling pathways, including the RAF/MEK/ERK and PI3K/AKT/mTOR pathways. Transforming mutations in KRAS are frequently found in pancreatic, colon, endometrial, ovarian and biliary cancers; almost all of these mutations result in constitutive activation of KRAS, thereby promoting cell proliferation (PMID: [21993244](#), [24651010](#)). KRAS mutations occur primarily in three major hotspots, G12, G13 and Q61, the first two of which occur in the GTP-ase domain and the latter interferes with the ability of NF1 to bind and regulate KRAS (PMID: [22589270](#), [21993244](#), [24651010](#)). Other less well-characterized mutations such as A146T/V/P and L19F have also been characterized and found to be activating albeit at lower frequencies (PMID: [20147967](#), [20432530](#), [20570890](#)). Germline KRAS mutations are responsible for both Noonan syndrome (NS) and cardio-facio-cutaneous (CFC) syndrome (PMID: [16474405](#), [16474404](#), [19467855](#), [17056636](#)) that are associated with hyperactivated MAPK pathway, distinctive clinical characteristics and a predisposition to cancer (PMID: [19467855](#), [17704260](#)).

## Variant Information

KRAS Q61H is a hotspot mutation in a GTP binding region that increases cell colony formation, basal activation of RAS, and expression of genes involved in cytoskeletal remodeling (PMID: [20147967](#)). This variant has less intrinsic GTPase activity than wild-type KRAS, thus maintaining KRAS in a GTP-bound, constitutively active state that promotes cell growth and other pro-survival pathways (PMID: [8524100](#)).

## Avutometinib+Defactinib



Avutometinib, a RAF/MEK clamp inhibitor, and defactinib, a FAK inhibitor, are FDA-approved in combination for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. FDA approval was based on the results of the Phase II RAMP-201 (NCT04625270) trial of avutometinib plus defactinib in 109 patients with recurrent LGSOC.

In the Phase II RAMP-201 (NCT04625270) trial, patients with KRAS-mutated LGSOC (n=57) demonstrated an overall response rate (ORR) of 44% (n=25), with a 2% (n=2) complete response (CR) rate, 40% (n=23) partial response (PR) rate and 49% (n=28) stable disease (SD) rate, a median duration of response (DOR) of 31.0 months (95% CI=14.8-31.1) and a median progression-free survival (PFS) of 22.0 months (95% CI=11.1-36.6) (PMID: [40644648](#)). Responders included patients with the following KRAS mutations: KRAS A146V, G12D, G12R, G12V and Q61H (PMID: [40644648](#)). Of patients with KRAS wildtype LGSOC (n=52), the cohort demonstrated an ORR of 17% (n=9), with a 17% (n=9) PR rate and 65% (n=34) SD rate, and a median PFS of 9.2 months (95% CI=5.5-NE) (PMID: [40644648](#)).

\*VAF: Variant Allele Frequency



# Com|PI|i|t DX Liquid

|      |   |           |            |
|------|---|-----------|------------|
| Name | - | Report No | 26xxxxxxGR |
|------|---|-----------|------------|

## 7. Clinical Trials to consider


### KRAS associated clinical trials

| NCT05874414      |                                                                                                | PHASE1   PHASE2 |
|------------------|------------------------------------------------------------------------------------------------|-----------------|
| <b>Title</b>     | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma |                 |
| <b>Treatment</b> | GNS561 + Trametinib                                                                            |                 |
| <b>Location</b>  | Puerto Rico, United States                                                                     |                 |

Press [here](#) for a live search of clinical trials for KRAS

# Com|P|i|t DX Liquid

|             |   |           |            |
|-------------|---|-----------|------------|
| Name        | - | Report No | 26xxxxxxGR |
| 8. Appendix |   |           |            |



**Figure 1.** Joint consensus recommendation of AMP, ACMG, ASCO and CAP for reporting genetic variants in cancer. [1-2]

1. Li MM, Datto M, Duncavage EJ, et al. J Mol Diagn. 2017 Jan;19(1):4-23.  
2. Leichsenring J, Horak P, Kreutzfeldt S, et al. Int J Cancer. 2019 Dec 1;145(11):2996-3010.



52, Spaton Ave., 15344, Gerakas, Greece, G.E.MI. nr: 0007856001000 | info@genekor.com, www.genekor.com | Tel. (+30) 210 6032138 Fax. (+30) 210 6032148  
A company certified with ISO 9001:2015 (Cert. No 041150049) and ISO/IEC 27001:2022(Cert. No 048190009)

George Nasioulas, PhD Molecular Biologist, Scientific Director, Medical ID:26025301255

Document Code: Δ21\_CCA\_Liquid



# Com|PI|i|t DX Liquid

Name

-

Report No

26xxxxxxGR

## Microsatellite Instability (MSI)

Microsatellite instability (MSI) is a condition of genetic hypermutability resulting from impaired DNA mismatch repair (MMR) mechanisms. It is characterized by the accumulation of mutations in short repetitive DNA sequences known as microsatellites. MSI-H is found across multiple cancer types, most notably in colorectal, endometrial, gastric, and ovarian cancer. It can arise sporadically or as part of Lynch syndrome, a hereditary condition caused by germline mutations in MMR genes (MLH1, MSH2, MSH6, PMS2).

The results of MSI are divided into three types: MSI-H, which means microsatellites are highly unstable; MSS, which means microsatellites are stable; MSI-U, which means that the sample does not meet the MSI evaluation conditions (tissues or pleural fluid samples may not have passed the MSI indicator calculation quality control due to the low DNA and/or content of tumor cells).

Pembrolizumab has received full FDA approval for adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors (PMID: 35680043, 33264544) — representing the first full approval for an immunotherapy based on a predictive biomarker, regardless of solid tumor type. This approval applies to patients who have progressed after prior treatment and have no satisfactory alternative options. Beyond the tumor-agnostic indication, specific approvals have been granted for tumor types such as endometrial and colorectal cancer.

Com|PI|i|t DX Liquid

Name-Report No26xxxxxGR

9. Biomarker findings across all Levels of evidence (A-D)

| Biomarker | Result                                      | Therapies with strong clinical significance    |                                             | Therapies with potential significance          |                                            | Therapies with potential resistance |
|-----------|---------------------------------------------|------------------------------------------------|---------------------------------------------|------------------------------------------------|--------------------------------------------|-------------------------------------|
|           |                                             | Approved/ Standard of care therapies (Level A) | Therapies in well powered studies (Level B) | Off label/ Investigational therapies (Level C) | Therapies in pre-clinical trials (Level D) |                                     |
| KRAS      | Exon 3<br>c.183A>C<br>(p.Q61H)<br>VAF: 0.6% | -                                              | -                                           | Avutometinib+Defa<br>ctinib                    | Trametinib<br>Cobimetinib<br>Binimetinib   | -                                   |



# Com|PI|i|t DX Liquid

Name

-

Report No

26xxxxxxGR

## 10. References

1. Francis G, Stein S. Circulating Cell-Free Tumour DNA in the Management of Cancer. Int J Mol Sci. 2015 Jun 19;16(6):14122-42. doi: 10.3390/ijms160614122. Review. (PMID: [26101870](#))
2. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. doi: 10.1038/nrclinonc.2013.110. (PMID: [23836314](#))
3. <https://civic.genome.wustl.edu/>
4. <http://cancer.sanger.ac.uk/>
5. <https://www.clinicaltrials.gov>
6. <http://atlasgeneticsoncology.org>
7. <https://www.oncokb.org/>
8. <https://www.mycancergenome.org/>
9. <https://pmkb.org/>
10. Smith G, et al. **Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.** Br J Cancer. 2010; 102:693-703. doi: 10.1038/sj.bjc.6605534 (PMID: [20147967](#))
11. Stephen AG, et al. **Dragging ras back in the ring.** Cancer Cell. 2014; 25:272-81. doi: 10.1016/j.ccr.2014.02.017 (PMID: [24651010](#))
12. Janakiraman M, et al. **Genomic and biological characterization of exon 4 KRAS mutations in human cancer.** Cancer Res. 2010; 70:5901-11. doi: 10.1158/0008-5472.CAN-10-0192 (PMID: [20570890](#))
13. Tidyman WE and Rauen KA. **The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.** Curr Opin Genet Dev. 2009; 19:230-6. doi: 10.1016/j.gde.2009.04.001 (PMID: [19467855](#))
14. Hellmann MD, et al. **Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.** Ann Oncol. 2019; 30:1134-1142. doi: 10.1093/annonc/mdz113 (PMID: [30918950](#))
15. Han J, et al. **MEK inhibitors for the treatment of non-small cell lung cancer.** J Hematol Oncol. 2021; 14:1. doi: 10.1186/s13045-020-01025-7 (PMID: [33402199](#))
16. Bollag G and McCormick F. **Intrinsic and GTPase-activating protein-stimulated Ras GTPase assays.** Methods Enzymol. 1995; 255:161-70. doi: 10.1016/s0076-6879(95)55020-8 (PMID: [8524100](#))
17. Niihori T, et al. **Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.** Nat Genet. 2006; 38:294-6. doi: 10.1038/ng1749 (PMID: [16474404](#))
18. Banerjee SN, et al. **Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.** J Clin Oncol. 2025; 43:2782-2792. doi: 10.1200/JCO-25-00112 (PMID: [40644648](#))
19. Schubert S, et al. **Germline KRAS mutations cause Noonan syndrome.** Nat Genet. 2006; 38:331-6. doi: 10.1038/ng1748 (PMID: [16474405](#))
20. Prior IA, et al. **A comprehensive survey of Ras mutations in cancer.** Cancer Res. 2012; 72:2457-67. doi: 10.1158/0008-5472.CAN-11-2612 (PMID: [22589270](#))
21. Fung AS, et al. **A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.** Lung Cancer. 2021; 157:21-29. doi: 10.1016/j.lungcan.2021.05.021 (PMID: [34052705](#))



# Com|Pl|i|t DX Liquid

| Name                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Report No  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 26xxxxxxGR |
| <p>22. Pylayeva-Gupta Y, et al. <b>RAS oncogenes: weaving a tumorigenic web.</b> Nat Rev Cancer. 2011; 11:761-74. doi: 10.1038/nrc3106 (PMID: <a href="#">21993244</a>)</p> <p>23. Ahearn IM, et al. <b>Regulating the regulator: post-translational modification of RAS.</b> Nat Rev Mol Cell Biol. 2011; 13:39-51. doi: 10.1038/nrm3255 (PMID: <a href="#">22189424</a>)</p> <p>24. Nava C, et al. <b>Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.</b> J Med Genet. 2007; 44:763-71. doi: 10.1136/jmg.2007.050450 (PMID: <a href="#">17704260</a>)</p> <p>25. Zenker M, et al. <b>Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.</b> J Med Genet. 2007; 44:131-5. doi: 10.1136/jmg.2006.046300 (PMID: <a href="#">17056636</a>)</p> <p>26. Higgs R. <b>Screening: A re-evaluation of KRAS mutational 'hotspots'.</b> Nat Rev Clin Oncol. 2010; 7:242. doi: 10.1038/nrclinonc.2010.54 (PMID: <a href="#">20432530</a>)</p> |            |